Metronidazole, Clindamycin, and Miscellaneous Agents

Metronidazole enters cells by passive diffusion. Within anaerobic organisms, the nitro group of the drug is reduced by anaerobic electron transport proteins, generating toxic metabolites that damage DNA — causing strand breakage and loss of the helical structure required for replication and transcription. The selectivity of this mechanism is absolute: reduction of the nitro group requires the low intracellular redox potential characteristic of anaerobic metabolism. Aerobic bacteria maintain a higher redox environment that does not reduce the nitro group, so the drug remains in its inactive prodrug form and exerts no antibacterial effect. This makes metronidazole one of the few antibiotics whose selectivity is based on the metabolic state of the target organism rather than a structural difference in a target enzyme.

Metronidazole is reliably active against virtually all clinically important anaerobes — Gram-negative anaerobes including Bacteroides fragilis and other Bacteroides species, Fusobacterium, and Prevotella species, as well as Gram-positive anaerobes including Clostridioides difficile, Clostridium perfringens, and Peptostreptococcus. Among protozoal pathogens, metronidazole is the drug of choice for Trichomonas vaginalis, Giardia lamblia, and Entamoeba histolytica. It has no activity against aerobic or facultatively anaerobic bacteria.

Oral bioavailability is approximately 80 to 100%, making oral and intravenous formulations essentially interchangeable in patients with functioning gastrointestinal tracts. Protein binding is low at approximately 10 to 20%, contributing to wide tissue distribution. Elimination is primarily hepatic; dose adjustment is not required for renal impairment, but dose reduction is warranted in severe hepatic impairment.

Central nervous system penetration is exceptional — metronidazole crosses the blood-brain barrier freely, achieving cerebrospinal fluid concentrations approaching plasma levels even without meningeal inflammation. This makes it one of the few oral agents capable of achieving therapeutic central nervous system concentrations for susceptible anaerobes, and underlies its use in brain abscess. It also achieves adequate concentrations in bile, vaginal secretions, and bone.

Metronidazole inhibits aldehyde dehydrogenase, the enzyme responsible for oxidizing acetaldehyde to acetate in ethanol metabolism, causing acetaldehyde accumulation when alcohol is consumed. The resulting reaction includes flushing, palpitations, nausea, vomiting, and headache — and in severe cases, hypotension and cardiovascular collapse. Patients must avoid all alcohol-containing beverages, foods prepared with wine or spirits, and alcohol-containing medications during therapy and for at least 48 hours after completing a course. This counseling must be explicit; patients frequently fail to recognize alcohol-containing sources such as certain mouthwashes or liquid medications.

Peripheral neuropathy is the most common neurological complication of metronidazole, manifesting as distal sensory numbness, tingling, and burning — particularly in the feet. It may be partially reversible after drug discontinuation but can be permanent with prolonged exposure. Central nervous system toxicity, while less common, includes cerebellar dysfunction (ataxia, dysarthria, nystagmus), encephalopathy, and seizures. Metronidazole-induced encephalopathy is reversible if the drug is promptly discontinued. Courses exceeding four weeks should be avoided where possible.

Metronidazole inhibits warfarin metabolism, resulting in clinically significant potentiation of anticoagulation. Patients on warfarin require close international normalized ratio monitoring when metronidazole is added, and warfarin dose reduction is frequently necessary. Metronidazole also reduces renal lithium clearance, increasing the risk of lithium toxicity. Common gastrointestinal effects include nausea, a metallic or bitter taste, and anorexia, which contribute to nonadherence in longer courses.

For intra-abdominal infections including complicated appendicitis, diverticulitis, and secondary peritonitis, metronidazole is combined with agents covering Gram-negative aerobes to provide comprehensive anaerobic and aerobic coverage. For brain abscess of odontogenic or sinogenic origin, where streptococci and anaerobes predominate, metronidazole combined with a third-generation cephalosporin is standard given its excellent central nervous system penetration. For bacterial vaginosis, oral metronidazole or vaginal gel is first-line treatment.

For Clostridioides difficile infection, oral vancomycin and fidaxomicin are now the preferred agents for all severity categories per current guidelines. Oral metronidazole is acceptable only when access to preferred agents is unavailable and must not be used for severe or complicated C. difficile infection.

Clindamycin binds the 50S ribosomal subunit, inhibiting protein synthesis. The binding site overlaps with those of macrolides and chloramphenicol, which has important cross-resistance implications. The drug is bacteriostatic at most clinical concentrations.

Beyond its antibacterial mechanism, clindamycin inhibits bacterial toxin production at sub-inhibitory concentrations by interfering with ribosomal translation of toxin genes. This is clinically exploited in severe toxin-mediated infections such as necrotizing fasciitis caused by Streptococcus pyogenes and toxic shock syndrome, where clindamycin is added specifically to suppress toxin synthesis even when the organism is being killed by a beta-lactam.

Clindamycin is active against methicillin-susceptible Staphylococcus aureus, many community-acquired methicillin-resistant Staphylococcus aureus strains, Streptococcus pyogenes, and viridans streptococci. For anaerobes, it covers most Gram-positive anaerobes including Clostridium species (excluding Clostridioides difficile, which is intrinsically resistant) and many Gram-negative anaerobes including Bacteroides fragilis, though resistance rates in B. fragilis now exceed 20 to 30% in many regions, limiting reliability as monotherapy for serious intra-abdominal infections. Clindamycin has no activity against aerobic Gram-negative bacteria or enterococci.

Oral bioavailability is approximately 90% and is not significantly affected by food. Distribution is excellent into bone, joints, lung, and soft tissue, with concentrations achieved within abscesses and phagocytes. Central nervous system penetration is poor and clindamycin is not appropriate for central nervous system infections. Elimination is primarily hepatic; no dose adjustment is required for renal impairment.

The most feared adverse effect of clindamycin is Clostridioides difficile infection. Clindamycin is among the antibiotics most strongly associated with C. difficile colitis, due to its profound disruption of normal colonic anaerobic flora that provides colonization resistance. Any patient who develops diarrhea during or after clindamycin therapy must be evaluated for C. difficile, even weeks after the course has been completed. Additional adverse effects include gastrointestinal upset, hepatotoxicity with elevated transaminases, and rare esophagitis if capsules are swallowed without adequate water.

The macrolide-lincosamide-streptogramin B resistance phenotype is the primary resistance mechanism relevant to clindamycin. The constitutive form confers high-level resistance to all three drug classes simultaneously. The inducible form presents a critical diagnostic challenge: organisms carrying an inducible resistance gene appear clindamycin-susceptible on routine disk diffusion. However, clindamycin therapy can induce resistance expression in vivo, leading to treatment failure.

The D-zone test detects inducible resistance: a blunted D-shaped zone of inhibition around the clindamycin disk in proximity to an erythromycin disk indicates inducible resistance, and clindamycin should be avoided despite apparent in vitro susceptibility. This test is essential before using clindamycin for methicillin-resistant Staphylococcus aureus when the isolate is erythromycin-resistant.

Fosfomycin inhibits an early step in peptidoglycan biosynthesis. This mechanism is entirely distinct from beta-lactam, glycopeptide, and all other cell wall agents, so fosfomycin retains activity against many organisms resistant to other cell wall-active drugs including extended-spectrum beta-lactamase-producing strains. In the United States, fosfomycin is available as a single 3-gram oral dose for uncomplicated lower urinary tract infection due to Escherichia coli and Enterococcus faecalis. It achieves extremely high urinary concentrations but inadequate systemic concentrations for infections outside the urinary tract. The single-dose regimen is favored from an antibiotic stewardship perspective.

Nitrofurantoin is reduced within bacterial cells to multiple reactive intermediates that simultaneously damage DNA, ribonucleic acid, ribosomes, and cell wall proteins. This multi-target mechanism is why resistance, though it exists, is uncommon. Nitrofurantoin achieves adequate antibacterial concentrations only in urine and is appropriate exclusively for lower urinary tract infection — it must never be used for pyelonephritis because it does not achieve bactericidal concentrations in renal tissue or the bloodstream.

Nitrofurantoin is not reliably active against Proteus mirabilis, Pseudomonas aeruginosa, or Klebsiella pneumoniae. It is contraindicated when creatinine clearance falls below 30 mL/min because inadequate urinary concentrations are achieved and toxicity risk increases. The most serious adverse effects are pulmonary toxicity — acute hypersensitivity pneumonitis or, with prolonged prophylactic use, chronic interstitial fibrosis — and hepatotoxicity. Both are rare with short courses but require monitoring with long-term use.

Trimethoprim-sulfamethoxazole produces sequential blockade of the bacterial folate synthesis pathway. Sulfamethoxazole competitively inhibits dihydropteroate synthase, blocking incorporation of para-aminobenzoic acid into the folate pathway, while trimethoprim inhibits dihydrofolate reductase, blocking reduction of dihydrofolate to tetrahydrofolate. The two drugs act on sequential steps, producing synergistic inhibition that prevents synthesis of tetrahydrofolate — the cofactor essential for purine and thymidine synthesis. This combination is bactericidal rather than merely bacteriostatic against susceptible organisms.

The spectrum includes most community-acquired Gram-negative Enterobacteriaceae when susceptible, Stenotrophomonas maltophilia (for which it is a primary treatment), community-acquired methicillin-resistant Staphylococcus aureus, Nocardia species, and Pneumocystis jirovecii — for which trimethoprim-sulfamethoxazole is both the preferred prophylactic agent and the drug of choice for treatment at higher doses. Adverse effects include sulfonamide hypersensitivity rash (which can progress to Stevens-Johnson syndrome), hyperkalemia from trimethoprim's blockade of renal tubular potassium secretion, elevation of serum creatinine without true reduction in glomerular filtration rate, myelosuppression (particularly with high-dose therapy), and photosensitivity.

Polymyxins bind to lipopolysaccharide in the outer membrane of Gram-negative bacteria and disrupt both the outer and inner membranes, causing rapid leakage of cytoplasmic contents and cell death. Polymyxins are active exclusively against Gram-negative bacteria.

The spectrum includes Pseudomonas aeruginosa, Acinetobacter baumannii, and most Enterobacteriaceae including carbapenem-resistant strains, making polymyxins among the very few options for carbapenem-resistant Acinetobacter baumannii and carbapenem-resistant Enterobacterales. Colistin is administered intravenously as colistimethate sodium — an inactive prodrug converted to active colistin in vivo. Polymyxin B is administered as the active form directly.

Nephrotoxicity is the primary dose-limiting adverse effect of colistin, occurring in a substantial proportion of patients receiving intravenous therapy. It is dose-dependent and often reversible but can be severe. Neurotoxicity — including facial paresthesias, dizziness, and peripheral neuropathy — and rare neuromuscular blockade also occur. Given the narrow therapeutic window and significant toxicity, polymyxins are strictly reserved for infections caused by organisms with no other active therapeutic options. They are not empiric drugs and must not be used for susceptible organisms.